// App-Quantinova.ai

: Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.

Researchers

Presenter

  • Jenny F. Seligmann

Principal Investigators

  • Thibaud Kossler

  • Murielle Mauer

  • Serge Evrard

  • Elske C. Gootjes

  • Jacob Freedman

  • Matthias Guckenberger

  • Anne-Sophie Govaerts

  • Anne Giraut

  • Jens Ricke

  • Gunnar Folprecht

  • Dirk Arnold

  • Ramesh Vishwakarma

  • Michel Ducreux

  • Theo JM Ruers

Medical Centers

  • Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom

  • Universitatsklinikum Carl Gustav Carus, Dresden, Germany

  • Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany

  • Gustave Roussy, Arcueil, France

  • Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

  • Geneva University Hospitals, Geneva, Switzerland

  • University Hospital of Zurich, Zurich, Switzerland

  • an Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

  • LMU Munich, Munich, Germany

  • Karolinska Institutet, Stockholm, Sweden

  • University Hospital of Bordeaux, Bordeaux, France

  • Radboudumc, Nijmegen, Netherlands

  • an Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

Locations

  • United Kingdom

  • Belgium

  • Netherlands

  • Switzerland

  • Sweden

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

  • Secondary liver cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ticilimumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

  • Non Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved